Classic congenital adrenal hyperplasia and puberty - PubMed (original) (raw)
Review
. 2004 Nov:151 Suppl 3:U77-82.
doi: 10.1530/eje.0.151u077.
Affiliations
- PMID: 15554890
- DOI: 10.1530/eje.0.151u077
Review
Classic congenital adrenal hyperplasia and puberty
Evangelia Charmandari et al. Eur J Endocrinol. 2004 Nov.
Abstract
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders resulting from deficiency of one of the five enzymes required for synthesis of cortisol in the adrenal cortex. The most common form of the disease is classic 21-hydroxylase deficiency, which is characterized by decreased synthesis of glucocorticoids and often mineralocorticoids, adrenal hyperandrogenism and impaired development and function of the adrenal medulla. The clinical management of classic 21-hydroxylase deficiency is often suboptimal, and patients are at risk of developing in tandem iatrogenic hypercortisolism and/or hyperandogenism. Limitations of current medical therapy include the inability to control hyperandrogenism without employing supraphysiologic doses of glucocorticoid, hyperresponsiveness of the hypertrophied adrenal glands to adrenocorticotropic hormone (ACTH) and difficulty in suppressing ACTH secretion from the anterior pituitary. Puberty imposes increased difficulty in attaining adrenocortical suppression despite optimal substitution therapy and adherence to medical treatment. Alterations in the endocrine milieu at puberty may influence cortisol pharmacokinetics and, consequently, the handling of hydrocortisone used as replacement therapy. Recent studies have demonstrated a significant increase in cortisol clearance at puberty and a shorter half-life of free cortisol in pubertal females compared with males. Furthermore, children with classic CAH have elevated fasting serum insulin concentrations and insulin resistance. The latter may further enhance adrenal and/or ovarian androgen secretion, decrease the therapeutic efficacy of glucocorticoids and contribute to later development of the metabolic syndrome and its complications.
Similar articles
- Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty.
Charmandari E, Hindmarsh PC, Johnston A, Brook CG. Charmandari E, et al. J Clin Endocrinol Metab. 2001 Jun;86(6):2701-8. doi: 10.1210/jcem.86.6.7522. J Clin Endocrinol Metab. 2001. PMID: 11397874 - [Congenital adrenal hyperplasia].
Stanić M, Nesović M. Stanić M, et al. Med Pregl. 1999 Nov-Dec;52(11-12):447-54. Med Pregl. 1999. PMID: 10748766 Review. Croatian. - Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty?
Charmandari E, Brook CG, Hindmarsh PC. Charmandari E, et al. Arch Dis Child. 2002 Apr;86(4):266-9. doi: 10.1136/adc.86.4.266. Arch Dis Child. 2002. PMID: 11919101 Free PMC article. Review. - Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications.
Charmandari E, Weise M, Bornstein SR, Eisenhofer G, Keil MF, Chrousos GP, Merke DP. Charmandari E, et al. J Clin Endocrinol Metab. 2002 May;87(5):2114-20. doi: 10.1210/jcem.87.5.8456. J Clin Endocrinol Metab. 2002. PMID: 11994350 - Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP. Charmandari E, et al. J Clin Endocrinol Metab. 2002 Jul;87(7):3197-200. doi: 10.1210/jcem.87.7.8652. J Clin Endocrinol Metab. 2002. PMID: 12107224
Cited by
- Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Newfield RS, Sarafoglou K, Fechner PY, Nokoff NJ, Auchus RJ, Vogiatzi MG, Jeha GS, Giri N, Roberts E, Sturgeon J, Chan JL, Farber RH. Newfield RS, et al. J Clin Endocrinol Metab. 2023 Oct 18;108(11):2871-2878. doi: 10.1210/clinem/dgad270. J Clin Endocrinol Metab. 2023. PMID: 37216921 Free PMC article. - Hydrocortisone dosing in children with classic congenital adrenal hyperplasia: results of the German/Austrian registry.
Hoyer-Kuhn H, Huebner A, Richter-Unruh A, Bettendorf M, Rohrer T, Kapelari K, Riedl S, Mohnike K, Dörr HG, Roehl FW, Fink K, Holl RW, Woelfle J. Hoyer-Kuhn H, et al. Endocr Connect. 2021 May 19;10(5):561-569. doi: 10.1530/EC-21-0023. Endocr Connect. 2021. PMID: 33909597 Free PMC article. - Metabolic Perspectives for Non-classical Congenital Adrenal Hyperplasia With Relation to the Classical Form of the Disease.
Macut D, Zdravković V, Bjekić-Macut J, Mastorakos G, Pignatelli D. Macut D, et al. Front Endocrinol (Lausanne). 2019 Oct 2;10:681. doi: 10.3389/fendo.2019.00681. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31632355 Free PMC article. Review. - Next Steps in Puberty Research: Broadening the Lens Toward Understudied Populations.
Deardorff J, Hoyt LT, Carter R, Shirtcliff EA. Deardorff J, et al. J Res Adolesc. 2019 Mar;29(1):133-154. doi: 10.1111/jora.12402. J Res Adolesc. 2019. PMID: 30869847 Free PMC article. Review. - Health problems of adolescent and adult patients with 21-hydroxylase deficiency.
Tajima T. Tajima T. Clin Pediatr Endocrinol. 2018;27(4):203-213. doi: 10.1297/cpe.27.203. Epub 2018 Oct 30. Clin Pediatr Endocrinol. 2018. PMID: 30393437 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical